How to Get Dayvigo (Lemborexant) in Maryland

What Dayvigo Is and Why It Requires a Prescription

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) that the FDA approved in December 2019 for the treatment of insomnia in adults who have difficulty with sleep onset or sleep maintenance. Unlike older sedative-hypnotics such as zolpidem, DORAs work by blocking wake-promoting orexin neuropeptides rather than broadly depressing central nervous system activity. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep compared with placebo and with zolpidem extended-release 6.25 mg at the primary Month 1 endpoint.

Because lemborexant is classified as a Schedule IV controlled substance by the DEA, every prescription in Maryland must originate from a provider who holds an active DEA registration and a valid Maryland Controlled Dangerous Substances (CDS) permit. This requirement applies equally to in-person and telehealth encounters, and it shapes the steps below.

Maryland Telehealth Prescribing Rules for Dayvigo

Maryland law permits telehealth prescribing of Schedule IV substances when the encounter meets certain standards. A synchronous audio-video visit satisfies the state's prescriber-patient relationship requirement, meaning you do not need an in-person office visit to get a Dayvigo prescription. The Maryland Board of Physicians and the Maryland Board of Nursing both recognize telehealth-established relationships for controlled substance prescribing, provided the prescriber documents a clinical evaluation consistent with American Academy of Sleep Medicine (AASM) guidelines.

Several national telehealth platforms and Maryland-based sleep clinics now offer insomnia consultations that can result in a Dayvigo prescription. The clinician will typically review your sleep history, screen for obstructive sleep apnea using validated instruments such as the STOP-Bang questionnaire, and confirm that cognitive behavioral therapy for insomnia (CBT-I) has been considered. The AASM clinical practice guideline recommends CBT-I as first-line therapy for chronic insomnia, so expect your provider to discuss behavioral interventions before or alongside pharmacotherapy.

A prescription generated through a compliant telehealth visit can be transmitted electronically to any Maryland-licensed pharmacy, including mail-order pharmacies. Maryland's electronic prescribing mandate for controlled substances means paper prescriptions are no longer the norm for Schedule IV drugs.

Which Providers Can Prescribe Dayvigo in Maryland

Three categories of clinicians can prescribe Dayvigo in Maryland: physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA). All must hold an active Maryland CDS permit and a DEA registration. Maryland NPs gained full practice authority in 2024, allowing them to prescribe controlled substances independently after meeting supervised-hour requirements. PAs prescribe under a delegation agreement with a supervising physician but are not restricted from prescribing Schedule IV medications.

Sleep medicine specialists represent the most common prescribers, though primary care physicians and psychiatrists also prescribe DORAs regularly. A 2020 analysis published in the Journal of Clinical Sleep Medicine found that primary care providers wrote approximately 60% of insomnia-related prescriptions nationally, indicating that you do not necessarily need a specialist referral to start Dayvigo.

Board-certified sleep physicians may be preferable when insomnia co-occurs with other sleep disorders. If you suspect obstructive sleep apnea or restless legs syndrome, a specialist can order polysomnography and tailor treatment accordingly. The U.S. Preventive Services Task Force has not issued a specific screening recommendation for insomnia, but the condition affects an estimated 10% to 15% of U.S. Adults according to NIH epidemiological data.

Insurance Coverage and Prior Authorization in Maryland

Most insurance plans in Maryland require prior authorization (PA) before covering Dayvigo. This applies to Maryland Medicaid, CareFirst BlueCross BlueShield, Aetna, and UnitedHealthcare plans sold on the Maryland Health Benefit Exchange. The PA process exists because DORAs are non-preferred on many formularies, and payers want documentation that the patient has tried or has a contraindication to lower-cost alternatives.

What PA documentation typically requires:

• A confirmed insomnia diagnosis meeting DSM-5 criteria (difficulty initiating or maintaining sleep, adequate sleep opportunity, associated daytime impairment, duration of at least three months for chronic insomnia).
• Evidence that the patient tried or considered CBT-I, consistent with the AASM clinical practice guideline.
• Trial and failure of, or documented intolerance to, at least one generic sleep medication (commonly zolpidem, trazodone, or suvorexant).
• Clinical rationale for selecting lemborexant over alternatives, which might include fall risk, substance use history, or prior paradoxical reactions to GABA-A agonists.

Maryland Medicaid covers Dayvigo with PA approval. Turnaround for a standard PA request is typically 3 to 7 business days, though urgent requests can be processed within 24 hours. If a PA is denied, both federal and state regulations guarantee the right to appeal. Your prescriber's office usually handles the PA submission, but you can track the status through your insurance portal or by calling the number on your member ID card.

For patients without insurance, the cash price for a 30-day supply of Dayvigo 5 mg or 10 mg often exceeds $400 at retail pharmacies. Eisai offers a manufacturer savings program that may reduce out-of-pocket costs for commercially insured patients, though eligibility requirements apply and government-funded insurance beneficiaries are excluded.

Pharmacy Access: Retail and 503A Options in Maryland

Once you have a valid prescription, you can fill Dayvigo at any Maryland-licensed retail pharmacy. CVS, Walgreens, Rite Aid, and independent pharmacies across the state stock Dayvigo, though availability may vary at smaller locations. Calling ahead to confirm stock is a practical step since Schedule IV medications are not always kept in quantity at every location.

Maryland also has licensed 503A compounding pharmacies that can prepare customized formulations when a prescriber determines that the commercially available tablet does not meet a patient's needs. A compounded version might be appropriate when a patient needs a dose not available commercially or cannot swallow tablets. The FDA's guidance on 503A compounding outlines the legal framework under which these pharmacies operate, including the requirement for an individual patient prescription.

Mail-order pharmacy is another option. Several pharmacy benefit managers (PBMs) operating in Maryland offer 90-day fills for maintenance medications. Since insomnia treatment is often long-term, a 90-day supply can reduce both cost per tablet and the number of refill visits. Your PBM's specialty or mail-order pharmacy must hold a Maryland non-resident pharmacy permit to ship controlled substances into the state.

What to Expect at Your First Appointment

Whether telehealth or in-person, the initial visit for a Dayvigo prescription follows a predictable clinical workflow. Your provider will take a focused sleep history, asking about sleep onset latency, number of nighttime awakenings, total sleep time, and daytime functional impairment. Expect questions about caffeine, alcohol, shift work, and screen habits.

No specific lab tests are required before starting Dayvigo. The FDA prescribing information does not mandate baseline blood work. Some clinicians order a basic metabolic panel or thyroid function tests to rule out medical causes of insomnia such as hyperthyroidism. If your provider suspects obstructive sleep apnea based on the STOP-Bang score or clinical presentation, a home sleep apnea test or in-lab polysomnography may be ordered before initiating DORA therapy.

The standard starting dose is 5 mg taken once nightly, no more than 30 minutes before bedtime, with at least 7 hours of intended sleep remaining. The SUNRISE-2 trial (N=949, 12-month duration) confirmed that both 5 mg and 10 mg doses maintained efficacy over long-term use, with the most common adverse effect being somnolence (reported in approximately 10% of the 10 mg group vs. 6% at 5 mg). Dose escalation to 10 mg is an option if 5 mg does not provide adequate relief after an appropriate trial period.

Patients taking moderate CYP3A inhibitors should not exceed 5 mg, and those on strong CYP3A inhibitors should avoid lemborexant entirely. Your prescriber will review your medication list for interactions with drugs like fluconazole, diltiazem, and clarithromycin.

How Dayvigo Compares to Other Insomnia Medications Available in Maryland

Maryland prescribers have access to the full range of FDA-approved insomnia therapies. Understanding where lemborexant fits helps contextualize why your provider might choose it or why your insurer's PA criteria reference alternatives.

Suvorexant (Belsomra) is the other FDA-approved DORA. A head-to-head study published in Sleep Medicine found that lemborexant 10 mg produced greater improvements in wake after sleep onset compared with suvorexant 20 mg at Week 4. Both drugs have Schedule IV classification and similar safety profiles, but formulary placement differs by plan.

Zolpidem and its extended-release formulation remain the most prescribed insomnia medications nationally according to IQVIA prescribing data. Generic zolpidem costs a fraction of brand-name DORAs, which is why insurers often require its trial before approving Dayvigo. Zolpidem carries higher risk of complex sleep behaviors per the FDA's 2019 boxed warning update, a consideration that may support a PA appeal when zolpidem is inappropriate.

Trazodone, prescribed off-label for insomnia at 25 to 100 mg, is another common step-therapy requirement despite limited high-quality RCT data supporting its use for this indication. The AASM's 2017 guideline does not recommend trazodone for sleep-onset or sleep-maintenance insomnia due to insufficient evidence, which can be cited in a PA appeal letter.

Transferring a Dayvigo Prescription to Maryland

If you are relocating to Maryland with an existing Dayvigo prescription from another state, the transfer process is straightforward. A pharmacist at your new Maryland pharmacy can initiate a prescription transfer from your out-of-state pharmacy, provided the prescription has remaining refills and was written by a provider licensed in the originating state. For controlled substances, some pharmacy chains handle transfers internally between their locations.

If refills are exhausted or the prescription has expired, you will need a new prescription from a Maryland-licensed provider. This is where telehealth platforms are particularly useful. A single synchronous visit with a Maryland-credentialed clinician can generate a new prescription that same day. Bring your prior treatment records and medication list to expedite the evaluation.

Timeline: From Consultation to First Dose

The total time from scheduling an appointment to taking your first Dayvigo tablet depends on two variables: appointment availability and PA processing time.

Telehealth platforms often offer appointments within 48 to 72 hours, sometimes sooner. If your provider determines Dayvigo is appropriate and your insurance does not require PA (or you are paying cash), the prescription can be sent to a pharmacy immediately after the visit. Retail pharmacies typically fill a controlled substance prescription within a few hours to one business day.

If PA is required, add 3 to 7 business days. Some practices use electronic PA systems like CoverMyMeds, which can cut turnaround to 2 to 3 business days. Worst-case scenario with a PA denial and subsequent appeal: 2 to 4 weeks. Peer-to-peer reviews between your prescriber and the insurer's medical director can sometimes reverse a denial within 48 hours. The National Council for Prescription Drug Programs standards govern electronic PA transactions, and Maryland has adopted these standards for its Medicaid program.

Patients starting Dayvigo should plan a follow-up visit 2 to 4 weeks after initiation to assess efficacy and tolerability. The SUNRISE-1 data showed that sleep latency improvements were measurable by the first night and reached statistical significance by Week 1, so you should have a sense of whether the medication is working before your follow-up.